{
    "Trade/Device Name(s)": [
        "RIGHTEST Blood Glucose Monitoring System Max Tel",
        "RIGHTEST Meter Max Tel",
        "RIGHTEST Blood Glucose Test Strip Max"
    ],
    "Submitter Information": "Bionime Corporation",
    "510(k) Number": "K231192",
    "Predicate Device Reference 510(k) Number(s)": [
        "K173638"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NBW"
    ],
    "Summary Letter Date": "January 19, 2024",
    "Summary Letter Received Date": "April 27, 2023",
    "Submission Date": "April 27, 2023",
    "Regulation Number(s)": [
        "21 CFR 862.1345"
    ],
    "Regulation Name(s)": [
        "Glucose Test System"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Fresh capillary whole blood"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "RIGHTEST Blood Glucose Meter Max Tel"
    ],
    "Method(s)/Technology(ies)": [
        "Amperometric detection",
        "Dehydrogenase electrochemical sensor"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "System",
        "Meter",
        "Test Strip",
        "Control Solution",
        "Lancing Device",
        "Sterile Lancets"
    ],
    "Document Summary": "FDA 510(k) summary for RIGHTEST Blood Glucose Monitoring System Max Tel, an over-the-counter system for quantitative self-testing of glucose using fresh capillary whole blood.",
    "Indications for Use Summary": "For self-testing by people with diabetes at home for quantitative measurement of glucose in fresh capillary whole blood from the fingertips, forearm, or palm as an aid to monitor the effectiveness of diabetes control; not for diagnosis, screening, or neonatal use.",
    "fda_folder": "Clinical Chemistry"
}